GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cessatech AS (XSAT:CESSA) » Definitions » Debt-to-Equity

Cessatech AS (XSAT:CESSA) Debt-to-Equity : 0.00 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cessatech AS Debt-to-Equity?

Cessatech AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Cessatech AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Cessatech AS's Total Stockholders Equity for the quarter that ended in Jun. 2024 was kr15.54 Mil. Cessatech AS's debt to equity for the quarter that ended in Jun. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cessatech AS's Debt-to-Equity or its related term are showing as below:

XSAT:CESSA's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cessatech AS Debt-to-Equity Historical Data

The historical data trend for Cessatech AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cessatech AS Debt-to-Equity Chart

Cessatech AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
- - - -

Cessatech AS Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cessatech AS's Debt-to-Equity

For the Biotechnology subindustry, Cessatech AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cessatech AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cessatech AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cessatech AS's Debt-to-Equity falls into.



Cessatech AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cessatech AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Cessatech AS's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cessatech AS  (XSAT:CESSA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Cessatech AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cessatech AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cessatech AS Business Description

Traded in Other Exchanges
Address
Kanonbadsvej 2, Copenhagen, DNK, 1437
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children.

Cessatech AS Headlines

No Headlines